Two companies active in carbon monoxide research, Alfama and hemoCORM, have merged to create a leader in the field of carbon monoxide-releasing molecules (CORM). Researchers at both companies have been developing compounds that can release carbon monoxide in minute amounts after oral or injectable administration, and have shown promise in a range of acute and chronic inflammatory diseases.

The founders of European start-ups Alfama and hemoCORM Ltd. are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.

The founders of European start-ups hemoCORM Ltd. and Alfama are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.